Antiplatelets pose risks of bleeding, decompensation in cirrhosis patients
In patients with cirrhosis, use of antiplatelets appears to contribute to increased risk of bleeding and decompensation events, according to a study. Meanwhile, nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with significant early bleeding only, whereas anticoagulants have a null effect on both outcomes.
